Waisi Eng
Chief Technology Officer Norroy North America Inc.
Seminars
Tuesday 1st December 2026
The Great Isotope Debate: Which Therapeutic Radionuclide Will Define the Next 5 Years of TRP Development? Seven Isotope Specialists, Seven Perspectives.
9:00 am
Experience a fast-paced debate, where isotope specialists will each present the strongest case for their radionuclide before joining a moderated discussion comparing clinical evidence, manufacturing readiness, supply considerations and commercial potential. Hear contrasting perspectives, challenge conventional thinking and take part in the discussion as the audience helps determine which isotope will define the next five years of TRP development.
- Comparing the scientific, clinical, manufacturing and commercial advantages of emerging isotopes including Actinium-225, Lead-212, Copper-67, Terbium, Astatine-211 and Lutetium-177
- Evaluating which radionuclides are best positioned to win across therapeutic efficacy, supply scalability, dosimetry flexibility, theranostic integration and global clinical applicability
- Challenging each isotope expert to defend why their radionuclide will become the hottest, most commercially impactful and most clinically transformative isotope over the next five years
Thursday 3rd December 2026
Advancing CAIX-Targeted Radiopharmaceuticals: Developing Next-Generation Precision Diagnostics for Clear Cell Renal Cell Carcinoma
2:30 pm
- Evaluating the clinical rationale for targeting CAIX to improve the detection and characterisation of clear cell renal cell carcinoma
- Optimising small molecule radiopharmaceutical design to enable same-day imaging and improved detection of primary and metastatic disease
- Generating early clinical evidence through investigator-initiated studies to validate target engagement, imaging performance and clinical translation
